We were thrilled and excited to come across this newly presented Synergo® data at the last Auro National Congress. Dr. Canepa, Dr. Campodonico and team presented their long term outcomes of treatment in Genova centres, Italy.
TEN YEARS EXPERIENCE WITH INTRAVESICAL THERMO-CHEMOTHERAPY MMC 40MG FOR NON MUSCLE INVASIVE BLADDER CANCER HIGH/INTERMEDIATE RISK
G. Canepa1, F. Campodonico1, S. Tamagno1, C. Introini2, M. Puntoni31 E.O. Ospedali Galliera, S.C. Urologia (Genova) 2 Ospedale Evangelico Internazionale, S.C. Urologia (Genova Voltri) 3 E.O. Ospedali Galliera, Direzione Scientifica e Biostatistica (Genova)
Aim of the study: evaluate the long-term experience on a treatment combining intravesical hyperthermia with Mytomicin C (HT-MMC) delivered with the Synergo® device.
More than 1600 treatments performed since 2004
146 Intermediate and High-risk NMIBC patients
37/146 patients reported a recurrence and 14/146 patients presented a progression.
The Recurrence Free Survival at 1, 2 and 5 years was 89.6%, 79.2 and 68.3 respectively.
Progression Free Survival at 1, 2 and 5 years was 98%, 96.2 and 83.7 respectively.
The number of treatment sessions for each patients were 10.4+/- 4.7 with a median of 11 sessions (Range 4-31). The time of exposure over 42°C was 37.4+/-7.4 mins. and the mean temperature was 42.0+/-0.8°C. The safety profile showed mainly grade 1 and 2 side effects. Ten patients complained grade 3 side-effects, including 1 patient bladder spasms/pain during treatment, 3 patients dysuria and 6 patients urgency after treatment.
Presented at: XXIII Congresso Nazionale Auro May 2016
